Vitamin Deficiencies Common in Children With Nocturnal Enuresis
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 1, 2024 -- Children with primary nocturnal enuresis may have vitamin D insufficiency and deficiency as well as vitamin B12 deficiency, according to a study published online June 10 in Annals of Medicine.
Hoda Atef Abdelsattar Ibrahim, from Cairo University, and colleagues examined the prevalence of vitamin D and vitamin B12 deficiencies in enuretic children. The analysis included 288 children seen at an outpatient clinic for nocturnal enuresis.
The researchers found that vitamin D insufficiency predominated (48.3 percent), while vitamin D deficiency was present in 31.3 percent. Vitamin B12 deficiency was seen in 25 percent of children. There was a stronger inverse correlation between vitamin D and the number of enuresis episodes per day than vitamin B12. A cutoff of 13.7 ng/mL for vitamin D was identified, below which failure to have dry nights was predicted. Protective factors for the absence of dry nights were higher vitamin D levels and behavioral treatment coexistence.
"Vitamin D insufficiency may be the most prevalent vitamin D abnormality in children with primary nocturnal enuresis. Vitamin D insufficiency may be more common in children with severe enuresis than vitamin B12 deficiency," the authors write. "This study may invite further research to examine the possible use of vitamin D and vitamin B12 as potential adjuvant therapies for children with primary nocturnal enuresis."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-02 06:00
Read more
- U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged 18 to 59 at Increased Risk for Disease
- Big Post-Election Surge Seen in Online Sales of Morning-After Pills
- How AI Might Help Men Fighting Prostate Cancer
- Nasal Swab Might Predict How Severe COVID Will Be
- Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
- Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions